|Bid||181.16 x 800|
|Ask||183.11 x 1100|
|Day's range||181.00 - 183.13|
|52-week range||176.36 - 242.99|
|Beta (5Y monthly)||0.66|
|PE ratio (TTM)||23.96|
|Earnings date||27 Oct 2021 - 01 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||258.45|
Here's why they selected Regeneron Pharmaceuticals (NASDAQ: REGN), Vertex Pharmaceuticals (NASDAQ: VRTX), and Viatris (NASDAQ: VTRS). Prosper Junior Bakiny (Regeneron Pharmaceuticals): Shares of Regeneron dropped like a rock amid September's broad market declines.
Here are three highly profitable stocks that Wall Street thinks will soar 39% or more within the next 12 months. The consensus price target for Bristol Myers Squibb (NYSE: BMY) is 39% above the big drugmaker's current share price. This forward earnings multiple is well below the average forward price-to-earnings ratio of 13.4 for pharmaceutical stocks in the S&P 500.
Vertex Pharmaceuticals (VRTX) closed at $181.34 in the latest trading session, marking a +0.63% move from the prior day.